John Lowney
Cardiovascular Disease · Warwick, RINPI 1003812769
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.8% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. GSK accounts for 70.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2020 at $153 and has fallen 82.7% since, to $27 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in RI, where the typical reported total is $360.
Across 18 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$249
- Merck$39
- Astellas Pharma US Inc$27
- UCB, Inc.$21
- Amgen$17
What the payments were for
- Food & beverage$33194%
- Education$226%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 13 | $249 |
| Merck | 2 | $39 |
| Astellas Pharma US Inc | 1 | $27 |
| UCB, Inc. | 1 | $21 |
| Amgen | 1 | $17 |
How this compares
$353 in reported general payments places this provider in the 45th percentile of 86 cardiovascular disease providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 341 | $318,856 |
| XareltoRivaroxaban | 261 | $240,019 |
| JardianceEmpagliflozin | 158 | $145,351 |
| EntrestoSacubitril/Valsartan | 145 | $140,963 |
| Metoprolol Succinate | 865 | $14,569 |
| Repatha SureclickEvolocumab | 18 | $9,403 |
| Atorvastatin Calcium | 553 | $7,929 |
| Losartan Potassium | 285 | $3,773 |
| Verapamil Er PmVerapamil Hcl | 14 | $3,565 |
| Rosuvastatin Calcium | 206 | $3,453 |
| Amlodipine Besylate | 387 | $3,073 |
| Metoprolol Tartrate | 259 | $2,878 |
| Amiodarone Hcl | 78 | $2,600 |
| Lisinopril | 187 | $2,147 |
| Bisoprolol Fumarate | 86 | $2,009 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Warwick
- Edward ThomasWarwick$15K
- Richard San AntonioWarwick$2K
- Kenneth SalzsiederWarwick$457
- Jennifer JarbeauWarwick$230
- Heather HurlburtWarwick$139
- John MurphyWarwick$128
- Ibrahim ElgabryWoonsocket$72K
- Ara SadaniantzProvidence$27K
- George BourganosWoonsocket$16K
- John CavaProvidence$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.